Treatment Differences and Long-term Outcomes in Adults and Children with Ewing Sarcoma

Strategic Insights -

Research published in Cancer Epidemiology has shed light on the differences in treatment practices and long-term outcomes in adults and children with Ewing sarcoma. A multi-institution retrospective cohort study was conducted in British Columbia, Canada, between January 2000 and December 2018, which included 107 individuals (66 adults, 41 children) with Ewing sarcoma. The study found that the 5-year overall survival (OS) rate was 58% in adults and 75% in children, with adults experiencing impaired progression-free survival (PFS) and OS compared to children.

Key Takeaways:

  • The study highlights the importance of timely initiation of treatment for Ewing sarcoma, with adult patients experiencing impaired PFS and OS compared to children.
  • The 5-year OS rate was significantly higher in children (75%) compared to adults (58%).
  • Patients with local disease had a 5-year OS rate of 74% in adults and 84% in children.
  • A Charlson Comorbidity Index (CCI) score of 3 was associated with impaired survival in adults and children.
  • The study suggests that treatment practices and long-term outcomes in adults and children with Ewing sarcoma may differ, emphasizing the need for more research in this area.
  • Ewing sarcoma is an aggressive malignancy primarily affecting children and adolescents, with limited research available on treatment practices in adults.
  • The study's findings may have implications for the development of more effective treatment strategies for adults with Ewing sarcoma.

Statistics:

  • 107 individuals (66 adults, 41 children) were included in the analysis.
  • 5-year OS rate: 58% in adults, 75% in children.
  • 5-year OS rate for patients with local disease: 74% in adults, 84% in children.
  • PFS HR: 1.8 (95% CI, 1.0 - 3.1; p=0.04) in adults.
  • OS HR: 1.8 (95% CI, 0.9 - 3.5; p=0.088) in adults.
  • CCI score of 3: associated with impaired survival in adults and children (HR, 3.9, 95% CI, 2.0 - 7.5; p=0.001)

Sources:

  • NewsRx. BC Cancer Agency Reports Findings in Ewing Sarcoma (Treatment differences and long-term outcomes in adults and children with Ewing sarcoma). Pediatrics Week. September 14, 2024; p 52.
  • Cancer Epidemiology. Treatment differences and long-term outcomes in adults and children with Ewing sarcoma. 2024:102653.